MA
SRRA

MYDA Advisors’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

MYDA Advisors’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-633
Closed -$75K – 199
2018
Q2 		$75K Buy
+633
New +$63.5K 0.03% 137

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MYDA Advisors's SRRA Position: Q3 2018 in Review

MYDA Advisors sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2018, closing a stake of 633 shares — an estimated $75K sold.

MYDA Advisors first reported a position in SRRA in Q2 2018 and held it in 1 quarter. The position peaked at $75K in Q2 2018. 60 funds tracked by Wall St. Rank hold SRRA as of Q3 2018.

  • MYDA Advisors reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • MYDA Advisors sold 633 Sierra Oncology, Inc. Common Stock shares in Q3 2018, an estimated $75K.
  • MYDA Advisors first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • MYDA Advisors's Sierra Oncology, Inc. Common Stock position peaked at $75K in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2018.

Based on MYDA Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.